[admin]

Global demand for sacubitril valsartan sodium (LCZ696) intermediates has intensified on a fixed clock. The US core patent expired in July 2023, and the China compound patent expires in 2026 — a window that compresses R&D, regulatory filing, and pre-launch inventory into a few short years. For procurement and technical teams at generic pharmaceutical companies, the binding constraint is rarely demand. It is sourcing: extended supply lead times for high-end specialty intermediates, volatile raw material pricing, inconsistent batch quality that interrupts production, and fragmented procurement across multiple suppliers that raises total cost.

Why LCZ696 Intermediate Sourcing Is a Multi-Stage Problem

Sacubitril valsartan sodium (CAS 936623904) is not a single purchase. It is a chain. The final drug substance is a 1:1 molar ratio co-crystal of sacubitril and valsartan, and the sacubitril portion is built through a sequence of chiral transformations — olefination, hydrogenation, deprotection — each of which produces an isolable intermediate with its own quality profile.

Buyers preparing for patent expiry therefore face a structural question: source each stage separately from a different vendor, absorbing coordination costs and quality risk at every hand-off, or find one supplier with uninterrupted coverage from chiral starting material through to the co-crystal API. The second option is materially easier to qualify, and it is where supplier differentiation now concentrates.

What Full-Chain LCZ696 Coverage Actually Looks Like

A complete product ladder on this route runs from early chiral building blocks to the finished co-crystal. Shandong Tianming Pharmaceutical Group supplies each documented node:

• N-[(1R)-2-[1,1′-Biphenyl]-4-yl-1-(hydroxymethyl)ethyl]carbamic acid tert-butyl ester (CAS 1426129501) — the chiral starting material for sacubitril synthesis
• Ethoxycarbonylmethylene triphenylphosphorane (CAS 5717373) — the Wittig reagent driving the olefination step
• (R,E)-5-([1,1′-Biphenyl]-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-pentenoic acid (CAS 1012341488) — the unsaturated intermediate formed by Wittig coupling
• (2R,4S)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid (CAS 1012341502) — the saturated chiral intermediate after hydrogenation
• (2R,4S)-Ethyl 5-([1,1′-biphenyl]-4-yl)-4-amino-2-methylpentanoate hydrochloride (CAS 149690120) — the deprotected chiral amine intermediate
• Sacubitril calcium salt (CAS 1369773396) — the advanced intermediate for co-crystal preparation, which also supports alternative new chemical entity development
• Sacubitril valsartan sodium (CAS 936623904) — the final co-crystal API

Covering these nodes in one place removes the multi-supplier coordination cost that defines fragmented procurement. It also means a single quality system governs every hand-off, rather than several systems a buyer must reconcile at filing.

Incoming Quality Control That Holds at Commercial Scale

The harder question is whether control survives the jump from laboratory batch to hundreds-of-tons annual output. Incoming quality control is where that is decided, because a specification that cannot be verified on receipt cannot be defended downstream.

Shandong Tianming Pharmaceutical Group operates full quality control from raw material receipt through in-process control to finished product release, under a GMP-compliant quality assurance system and ISO9001 certification (Shandong Sihuan Pharmaceutical Co., Ltd., 2025; Guangxi Tianming Pharmaceutical Co., Ltd., 2024). On the sacubitril series, monitoring is applied to the sacubitril-to-valsartan molar ratio, chiral impurities, residual solvents, particle size, and crystal form — the attributes that determine whether a co-crystal API performs in formulation. Sacubitril calcium is controlled to individual impurity below 0.1% and chiral purity above 99.5%.

Full batch traceability is maintained across reaction parameters, purification processes, and testing data, with all records archived for chain-of-custody traceability. For buyers building a comparability argument, that audit trail is the deliverable.

Scale, Documentation, and Regulatory Readiness

Three production bases with over 160 reactor vessels and annual capacity in the hundreds of tons underpin gram-level to ton-level supply, spanning laboratory R&D, pilot batches, and commercial production. Documentation is provided as standard: COA, MOA methodology, impurity profile studies, and stability data supporting DMF and CEP global regulatory filings, alongside structural confirmation documentation for all products.

Analytical infrastructure at the two R&D centers in Jinan and Nanjing includes HPLC, gas chromatography, mass spectrometry, LC-MS, and chiral analysis instruments, in laboratories exceeding 6,000 square meters. The group invests above 10% of annual revenue in R&D, with an additional 1% allocated to management system iteration.

Practical Checks for Evaluating an Intermediate Partner

The following questions separate capable suppliers from those that merely list a catalogue:

• Can the supplier name every route node it controls, or only the final API?
• Which quality attributes are measured on incoming material, and how are they archived?
• Is batch traceability continuous from raw material receipt to release?
• Does documentation support DMF and CEP filing, or must the buyer assemble it?
• What are actual lead times for in-stock versus made-to-order material?
• What technical support exists after delivery?

On the last three, Shandong Tianming Pharmaceutical Group delivers in-stock orders within 7–15 working days, resolves routine technical issues with reference solutions within 2 hours, and resolves complex technical issues in a written report within 24 hours, under a 1-on-1 account manager plus technical engineer model.

The Position of Shandong Tianming Pharmaceutical Group

Founded in 2020 and evolving from Shandong Sihuan Pharmaceutical Co., Ltd. (established 2010), the group coordinates two R&D centers, three domestic production bases, and two overseas business entities, serving 2,000+ cooperative customers with 400+ employees and holding 20 invention patents and 40 utility model patents. Its LCZ696 offering sits alongside full-chain intermediates for orforglipron and finerenone production, giving buyers with multi-program pipelines a consolidated source.

For teams tasked with securing LCZ696 intermediates before 2026, the practical test is not whether a supplier lists the compound. It is whether the supplier can carry the route, prove the quality at every node, and document it well enough to file.

Home

Tianming Pharmaceutical Group

[Author]

Posts